Aquestive Therapeutics, Inc.
AQST · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $57,561 | $50,583 | $47,680 | $50,832 |
| % Growth | 13.8% | 6.1% | -6.2% | – |
| Cost of Goods Sold | $17,872 | $20,831 | $19,386 | $14,989 |
| Gross Profit | $39,689 | $29,752 | $28,294 | $35,843 |
| % Margin | 69% | 58.8% | 59.3% | 70.5% |
| R&D Expenses | $20,280 | $13,104 | $17,481 | $17,047 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $50,180 | $31,750 | $52,879 | $53,475 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $70,460 | $44,854 | $70,360 | $70,522 |
| Operating Income | -$30,771 | -$15,102 | -$42,066 | -$34,679 |
| % Margin | -53.5% | -29.9% | -88.2% | -68.2% |
| Other Income/Exp. Net | -$13,380 | $7,477 | -$12,344 | -$35,860 |
| Pre-Tax Income | -$44,151 | -$7,625 | -$54,410 | -$70,539 |
| Tax Expense | -$14 | $245 | $0 | $0 |
| Net Income | -$44,137 | -$7,870 | -$54,410 | -$70,539 |
| % Margin | -76.7% | -15.6% | -114.1% | -138.8% |
| EPS | -0.51 | -0.13 | -1.12 | -1.85 |
| % Growth | -292.3% | 88.4% | 39.5% | – |
| EPS Diluted | -0.51 | -0.13 | -1.12 | -1.85 |
| Weighted Avg Shares Out | 86,726 | 61,256 | 48,734 | 38,078 |
| Weighted Avg Shares Out Dil | 86,726 | 61,256 | 48,734 | 38,078 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3,437 | $16,321 | $99 | $423 |
| Interest Expense | $16,817 | $7,462 | $12,443 | $22,461 |
| Depreciation & Amortization | $718 | $1,345 | $2,387 | $2,964 |
| EBITDA | -$26,616 | $1,182 | -$39,580 | -$45,114 |
| % Margin | -46.2% | 2.3% | -83% | -88.8% |